GlassScriptPhysician profile
Manohar Ahuja
NPI 1467426064
$34,555.24
in general payments reported to CMS, 2019-2025
44 companies · $6,580 in 2025
The $6,580 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,392 · 2020: $535 · 2021: $1,490 · 2022: $774 · 2023: $2,122 · 2024: $20K · 2025: $6,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $6,871 · Travel and Lodging: $1,761 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,570.00 |
| Food and Beverage | $6,871.03 |
| Travel and Lodging | $1,761.19 |
| Education | $162.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $17,010.63 | 2024-2025 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,586.60 | 2021-2025 | Jardiance |
| Astrazeneca Uk Limited | $1,770.61 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,614.24 | 2019-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $1,334.54 | 2021-2025 | |
| Amgen INC. | $1,192.75 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Novartis Pharmaceuticals Corporation | $880.69 | 2023-2025 | |
| Ani Pharmaceuticals, INC. | $638.10 | 2022-2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $632.48 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $540.69 | 2019-2023 | Korsuva, Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $422.03 | 2022-2025 | |
| Horizon Therapeutics Plc | $417.39 | 2019-2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $378.16 | 2019-2025 | Ultomiris |
| Daiichi Sankyo INC. | $356.14 | 2019-2023 | Injectafer |
| Glaxosmithkline, LLC. | $332.46 | 2021-2025 | Benlysta |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manohar Ahuja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.